Cargando…
Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been established. The lack of availability of ultra-sensitive assays is one critical issue that has impeded progress. The le...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520820/ https://www.ncbi.nlm.nih.gov/pubmed/28733956 http://dx.doi.org/10.1007/s40120-017-0074-8 |